Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  La Jolla Pharmaceutical Company    LJPCD

No quotes available
-- USD   0.00%
09/07 LA JOLLA PHARMA : Announces Agreement with European Medicines Agency..
09/07 LA JOLLA PHARMA : Reports Positive Results from Phase 1 Study of LJP..
08/08 LA JOLLA PHARMA : posts 2Q loss
SummaryQuotesNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

LA JOLLA PHARMACEUTICAL COMPANY : REVERSE SPLIT: 1 of 50

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/14/2014 CEST
A split is applied today to La Jolla Pharmaceutical Company's stock price.


© Factset 2014
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LA JOLLA PHARMACEUTICAL CO
09/19 LA JOLLA PHARMACEUTICAL CO : Other Events, Financial Statements and Exhibits (fo..
09/08 LA JOLLA PHARMACEUTICAL CO : Other Events, Financial Statements and Exhibits (fo..
09/07 LA JOLLA PHARMACEUTICAL COMPANY : Announces Agreement with European Medicines Ag..
09/07 LA JOLLA PHARMACEUTICAL COMPANY : Reports Positive Results from Phase 1 Study of..
08/26 LA JOLLA PHARMACEUTICAL CO : Change in Directors or Principal Officers, Submissi..
08/18 LA JOLLA PHARMACEUTICAL COMPANY : Announces Financial Results for the Three and ..
08/12 LA JOLLA PHARMACEUTICAL CO : Results of Operations and Financial Condition, Fina..
08/08 LA JOLLA PHARMACEUTICAL : posts 2Q loss
08/08 LA JOLLA PHARMACEUTICAL COMPANY : Announces Financial Results for the Three and ..
08/08 LA JOLLA PHARMACEUTICAL : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
More news
Sector news : Bio Therapeutic Drugs
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
More sector news : Bio Therapeutic Drugs
Advertisement
Financials ($)
Sales 2016 1,83 M
EBIT 2016 -65,9 M
Net income 2016 -65,8 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 255x
Capi. / Sales 2017 872x
Capitalization 466 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 35,8 $
Spread / Average Target 40%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
George Francis Tidmarsh President, CEO, Secretary & Director
Kevin C. Tang Chairman
Jennifer Carver Senior Vice President-Operations
Dennis M. Mulroy Chief Financial & Accounting Officer
James M. Rolke Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LA JOLLA PHARMACEUTICA..0.00%466
AMGEN, INC.4.55%127 004
GILEAD SCIENCES, INC.-21.96%104 213
CELGENE CORPORATION-11.63%82 030
REGENERON PHARMACEUTIC..-22.80%44 129
VERTEX PHARMACEUTICALS..-29.40%22 013
More Results